Diabetes: What Roles Does DPP4 Inhibition Have?
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 13787
Special Issue Editor
Special Issue Information
Dear Colleagues,
DPP4 inhibition was the first new medicine for type 2 diabetes mellitus (T2DM) in the 21st century, having its origins in the 1990s. The path to a therapy began with the discovery that DPP4 is the most important protease that inactivates GLP1. Until then, the focus of DPP4 research was in its immunological roles. The discoveries that DPP4 is the major receptor for infection of human cells by the MERS virus, and severe MERS is associated with T2DM, linked DPP4 also with virology. Naturally, potential roles for DPP4 in Covid_19 are being studied. Research on DPP4 inhibition has investigated potential benefits for diabetes complications such as cardiovascular disease, fatty liver and inflammation as well as associations between DPP4 and obesity and turning towards immunology and cancer biology.
DPP4 is a multifunctional protein having numerous biological roles because it cuts and inactivates many substrates. Much of the challenge has been to identify the size, circumstances and impact of DPP4 mediated effects.
This special issue will contain all these aspects of DPP4 in biology and medicine, according to the areas of interest to the invited authors.
Prof. Dr. Mark Gorrell
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DPP4
- diabetes
- diabetes complications
- pathogenesis
- therapy
- cancer biology
- immunology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
